Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASPH | Q12797 | 3/20 | 0.41 |
| ▸ | KDM8 | Q8N371 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | RIOX2 | Q8IUF8 | 2/20 | 0.41 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.40 |
| ▸ | PDE9A | O76083 | 2/20 | 0.39 |
| ▸ | AURKA | O14965 | 6/20 | 0.37 |
| ▸ | RPS6KB1 | P23443 | 6/20 | 0.37 |
| ▸ | ACP1 | P24666 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 3/20 | 0.37 |
| ▸ | PPARD | Q03181 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1300548 | 1.00 | ASPH (0.41) | ASPHKDM8KDM4ERIOX2METTL3 | |
| SCHEMBL1301716 | 0.92 | METTL3 (0.43) | METTL3AURKARPS6KB1AURKB | |
| SCHEMBL1301717 | 0.92 | METTL3 (0.43) | METTL3AURKARPS6KB1AURKB | |
| SCHEMBL1300290 | 0.91 | METTL3 (0.43) | ASPHKDM8KDM4ERIOX2METTL3 | |
| SCHEMBL1300294 | 0.91 | METTL3 (0.43) | ASPHKDM8KDM4ERIOX2METTL3 | |
| SCHEMBL1301348 | 0.90 | METTL3 (0.40) | ASPHKDM8KDM4ERIOX2METTL3 | |
| SCHEMBL1301351 | 0.90 | METTL3 (0.40) | ASPHKDM8KDM4ERIOX2METTL3 | |
| SCHEMBL1300641 | 0.90 | METTL3 (0.44) | ASPHKDM8KDM4ERIOX2METTL3 | |
| SCHEMBL1300646 | 0.90 | METTL3 (0.44) | ASPHKDM8KDM4ERIOX2METTL3 | |
| SCHEMBL1300784 | 0.90 | METTL3 (0.43) | ASPHKDM8KDM4ERIOX2METTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269741-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269741-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110166123-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | AARDEA BIOSCIENCES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166123-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | TYMP, SAMHD1, PNP | ASPH 303/4885KDM8 177/4885KDM4E 656/4885 |
| US-20110269741-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | TYMP, SAMHD1, PNP | ASPH 303/4885KDM8 177/4885KDM4E 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.